Cytel, the leading provider of adaptive
clinical trial services and software, announced today that its Dr. Jerald Schindler and
Dr. Nitin Patel will present case studies and lead discussions at the Center for
Business Intelligence (CBI) Dose Finding Clinical Trial conference to be held February
26 - 27 in West Conshohocken, PA. The meeting will focus on the biopharmaceutical
industry's widening application of recently-developed adaptive methods in early-
phase dosing clinical studies.
Cytel's Dr. Schindler and Dr. Patel will be joined by fellow experts from both
academia and major biopharmaceuticals, including Merck, Novartis, Millennium,
Glaxo Smith Kline, Bristol-Myers Squibb and Johnson & Johnson. The wide array of
companies exploring adaptive dose-finding clearly indicates the industry's belief that
these innovative methods provide better data for the dose-selection decisions that
are crucial to more efficient and successful confirmatory trials.
As Chairman of the two-day conference Dr. Schindler, President, Cytel
Pharmaceutical Research Division, kicks off the day-one agenda with an outline of
how utilization of Cytel's adaptive statistical methodologies and resultant design are
particularly well-suited to the all-important dose-finding phase. Dr. Schindler will
also discuss the readiness of both the FDA and the EMEA to accept and approve dose
finding data.
Dr. Patel, Co-founder, Chairman and CTO, of Cytel, Inc., will discuss an innovative
software tool developed jointly with Merck Research Labs that simulates adaptive
dose allocation and compares the efficiency of adaptive Bayesian and frequentist
methods to traditional designs. This tool effectively identifies for Merck the
advantage innovative methods provide when planning their early phase studies.
"Our simulations support the broad conclusion that for the same sample size, the
Bayesian method gives a mean squared error that is approximately half that of the
traditional design for estimating the mean response at every dose level," reports Dr.
Patel.
Clinical development professionals interested in attending can find complete
conference speakers, agenda and registration information at:
cbinet/show_conference.cfm?confCode=HB709
or via cytel.
Dr. Schindler and Dr. Patel will be available for interviews during the conference to
industry press and analysts. To schedule, please contact:
Michael Weitz
Marketing Communications Director
mikecytel
+1.617.661.2011
About Cytel
Cytel Inc. (cytel) is the leading provider of clinical trial consulting services
and specialized statistical software for the biopharmaceutical, medical device,
academic, and research institute markets. Cytel's innovative trial designs reduce
development costs and lead times and facilitate better decisions that increase the
probability of clinical trial success. Entering its 20th year, Cytel Inc. is
headquartered in Cambridge MA, with software development and statistics
outsourcing facilities in Pune, India.
About CBI Research, Inc.
CBI is a privately held, world-class conference company that focuses on producing
high-level programs for executive decision-makers who face strategic issues in
domestic and international markets. CBI has provided information and networking
opportunities for thousands of senior-level executives in various industries. More
information at cbinet